A recent grant collaboration, funded by Innovate UK, between Sphere Fluidics, University of Edinburgh, Horizon Discovery, OXGENE, and Twist Bioscience has culminated in a prototype automated microfluidic genome editing platform.
The benchtop device integrates and miniaturizes the multi-step process for creating genome-edited cell lines, from transfection to validation of the edited cell.
Dr. Steven Pollard, University of Edinburgh
To learn more, we spoke with Professor Steven Pollard, Group Leader at the Centre for Regenerative Medicine and Edinburgh Cancer Research Centre at the University of Edinburgh. We also discuss some of his latest work to understand the biology of brain cancer using CRISPR/Cas technology and optimized genome editing workflows.
Read the full interview here!
Sphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows